Opinions
Jim Cramer - Mad Money
Revance Therapeutics
RVNC-Q
DON'T BUY
Mar 26, 2021
$28.030
Stock price when the opinion was issued
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
Advertising
Abbvie as competition Abbvie's CEO hasn't turned the juice on Allergan (a company ABBV bought last year) and he's very competitive. When he turns it on, it will hurt EVNC. Be careful with RVNC. He wishes he liked Revance more. He knows this group (aesthetics) and Abbvie produces the popular Botox.